In a media event today, it was announced UK has been selected as a site for KidCOVE, a national research study to ensure a safe and effective vaccine that protects children ages 6 months through 11 years from getting sick with COVID-19.
Using the Moderna vaccine currently authorized for adults, this pediatric research study will define an age-appropriate dose for children, test the vaccine’s effectiveness, and monitor any potential side effects, collecting information to ensure safe use.
George Fuchs, MD, principal investigator, professor of pediatrics, chief of pediatric gastroenterology and vice chair for clinical affairs at Kentucky Children’s Hospital, and John Baur, PhD, co-investigator and professor of pediatrics and neonatology, will oversee the study at UK.
This study builds on UK’s previous success with COVID-19 vaccine studies, including serving as the top-enrolling site in the world for the Phase 3 Johnson & Johnson trial. UK is now fully operational with four vaccine studies: two Johnson & Johnson trials (ongoing for participant monitoring and data collection), PreventCovidU (studying how COVID is spreading among both vaccinated and unvaccinated people 18 to 29 years old), and KidCOVE.
More information about each study is available at StopCOVIDKy.com.
For more information, read the UKNow article, UK Begins Recruitment for Moderna Vaccine in Young Children.